Advances in pharmacotherapy for treating endometriosis
The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Endometriosis is an estrogen-dependent chronic disease requiring long-term therapy. Therefore, the choice of medical treatment should be based on efficacy, preference of patients, incidence and severity of adverse effects and cost. AREAS COVERED: This review briefly summarizes the currently available medical treatment for endometriosis. The treatments most recently proposed for endometriosis will be described in detail, including gonadotropin-releasing hormone (GnRH) antagonists, aromatase inhibitors (AIs) and the flexible extended combined oral contraceptive. EXPERT OPINION: The oral contraceptive pill and progestogens allow for the treatment of the majority of patients with endometriosis. The flexible extended dosing regimen, containing drospirenone and ethinylestradiol, may be particularly useful in patients suffering severe dysmenorrhea and improving the adherence and compliance with treatment. GnRH agonists may be used in patients resistant to first-line therapy; up to now, limited data are available on the use of GnRH antagonist (such as elagolix) in patients with endometriosis. AIs should be regarded as experimental therapies and used only in patients with symptoms resistant to other therapies; however, the use of these drugs is limited by the possibility to administer the treatment for short-term periods only (6 months) and, similarly to GnRH antagonists, by the high incidence of adverse effects, requiring the use of add-back therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ESHRE guideline: management of women with endometriosis
Dunselman, G. A. J., Vermeulen, N., Becker, C., Calhaz-Jorge, C., D'Hooghe, T., De Bie, B., Heikinheimo, O., Horne, A. W., Kiesel, L., Nap, A., et al. (2014) · Human Reproduction · doi:10.1093/humrep/det457 · Cited by 2,211
High prevalence of endometriosis in infertile women with normal ovulation and normospermic partners
Meuleman, C., Vandenabeele, B., Fieuws, S., Spiessens, C., Timmerman, D., & D'Hooghe, T. (2009) · Fertility and Sterility · doi:10.1016/j.fertnstert.2008.04.056 · Cited by 606
Consensus on current management of endometriosis
Johnson, N. P., Hummelshoj, L., for the World Endometriosis Society Montpellier Consortium, Abrao, M. S., Adamson, G. D., Allaire, C., Amelung, V., Andersson, E., Becker, C., Birna Árdal, K. B., et al. (2013) · Human Reproduction · doi:10.1093/humrep/det050 · Cited by 558
Vercellini, P., Trespidi, L., Colombo, A., Vendola, N., Marchini, M., & Crosignani, P. G. (1993) · Fertility and Sterility · doi:10.1016/s0015-0282(16)56039-7 · Cited by 311
Vercellini, P., Frontino, G., De Giorgi, O., Pietropaolo, G., Pasin, R., & Crosignani, P. G. (2003) · Fertility and Sterility · doi:10.1016/s0015-0282(03)00794-5 · Cited by 289 · cited 1×
“The incidence of dysmenorrhea decreased after the use of continuous COC for 2 years [14].”
MethodHarada, T., Momoeda, M., Taketani, Y., Hoshiai, H., & Terakawa, N. (2008) · Fertility and Sterility · doi:10.1016/j.fertnstert.2007.08.051 · Cited by 289 · cited 1×
“More recently, the efficacy of COCs in the treatment of dysmenorrhea caused by endometriosis is demonstrated in a double-blind RCT, where COC is compared with placebo [13].”
BackgroundTreatment of severe postmenopausal endometriosis with an aromatase inhibitor
Takayama, K., Zeitoun, K., Gunby, R. T., Sasano, H., Carr, B. R., & Bulun, S. E. (1998) · Fertility and Sterility · doi:10.1016/s0015-0282(98)00022-3 · Cited by 270
Vercellini, P., Frontino, G., De Giorgi, O., Aimi, G., Zaina, B., & Crosignani, P. G. (2003) · Fertility and Sterility · doi:10.1016/s0015-0282(03)00608-3 · Cited by 263
Soysal, S. (2004) · Human Reproduction · doi:10.1093/humrep/deh035 · Cited by 227 · cited 2×
“AIs could play a role in preventing the recurrence of endometriosis after surgical treatments; three RTCs investigating this issue reported conflicting results [74,78,79].”
ResultScholes, D., LaCroix, A. Z., Ichikawa, L. E., Barlow, W. E., & Ott, S. M. (2005) · Archives of Pediatrics & Adolescent Medicine · doi:10.1001/archpedi.159.2.139 · Cited by 221 · cited 1×
“Studies in adolescents have demonstrated that bone loss is regained after MPA discontinuation, even in younger users [51].”
Background
Cited by
Leone Roberti Maggiore, U., Ferrero, S., Candiani, M., Somigliana, E., Viganò, P., & Vercellini, P. (2017) · European Urology · doi:10.1016/j.eururo.2016.12.015 · Cited by 187
“[80] Tafi E, Leone Roberti Maggiore U, Alessandri F, et al.”
BackgroundSelf-citationCurrent and emerging treatment options for endometriosis
Ferrero, S., Evangelisti, G., & Barra, F. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1494154 · Cited by 152
“therapy has a pivotal role in the long-term treatment of endometriosis [5,6].”
BackgroundSelf-citationBarra, F., Scala, C., & Ferrero, S. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1461840 · Cited by 100
Self-citationHarada, T., Kosaka, S., Elliesen, J., Yasuda, M., Ito, M., & Momoeda, M. (2017) · Fertility and Sterility · doi:10.1016/j.fertnstert.2017.07.1165 · Cited by 84
Impact of surgery for endometriosis on the outcomes of in vitro fertilization
Ferrero, S., Gazzo, I., Crosa, M., Rosato, F. P., Barra, F., & Leone Roberti Maggiore, U. (2024) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2024.102496 · Cited by 17
Self-citation
Metadata
- Authors
- Tafi, E., Leone Roberti Maggiore, U., Alessandri, F., Bogliolo, S., Gardella, B., Vellone, V. G., Grillo, F., Mastracci, L., & Ferrero, S.
- Venue
- Expert Opinion on Pharmacotherapy
- Publisher
- Informa Healthcare
- Published
- 2015-09-07
- Volume
- 16
- Issue
- 16
- Pages
- 2465-2483
- ISSN
- 1465-6566 (ISSN-L)
- 1744-7666
- OpenAlex
- W2175100915
- Cited by
- 36
- References
- 35
- FWCI
- 4.59
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Advances in pharmacotherapy for treating endometriosis. https://app.cochat.ai/papers/10.1517/14656566.2015.1085510
- The paper
- Tafi, E., Leone Roberti Maggiore, U., Alessandri, F., Bogliolo, S., Gardella, B., Vellone, V. G., Grillo, F., Mastracci, L., & Ferrero, S. (2015). Advances in pharmacotherapy for treating endometriosis. Expert Opinion on Pharmacotherapy. https://doi.org/10.1517/14656566.2015.1085510
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.